Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06203158
Status:
COMPLETED
Last Update Posted:
2024-03-08
First Post:
2023-12-20
Brief Title:
Intestinal Epithelial Fucosylation Affects the Efficacy of Ustekinumab in Crohns Disease
Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Organization:
Second Affiliated Hospital of Wenzhou Medical University
Study Overview
Official Title:
Intestinal Epithelial Fucosylation Affects the Efficacy of Ustekinumab in Crohns Disease
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The loss of response rate of ustekinumabUST is high and the specific mechanism has not yet been elucidated Molecular markers that can accurately predict the efficacy of UST are urgently needed to provide theoretical basis for guiding individualized treatment Therefore this study intends to explore the impact of intestinal epithelial fucosylation levels on the efficacy of UST in patients with Crohns diseaseCD aiming to provide predictable molecular markers for UST to accurately treat CD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None